文献速递腹部介入USDSA

肿瘤硬度与肝细胞癌经导管动脉化疗栓塞治疗反应相关性的初步研究

Tumour stiffness associated with tumour response to conventional transarterial chemoembolisation for hepatocellular carcinoma: preliminary findings.
PubMed 文献 · Clin Radiol · 2019-08-14

回顾性队列研究纳入59例不可切除肝细胞癌患者,TACE术前用声辐射力脉冲成像测量肿瘤及非肿瘤肝组织硬度,发现肿瘤硬度及肿瘤与非肿瘤肝硬度差与TACE治疗反应显著相关(p=0.019和0.010),肿瘤硬度<2 m/s或硬度差<0.5者更可能出现治疗反应;硬度差也是总生存期的显著预测因素之一,但多变量分析中甲胎蛋白和BCLC分期为独立预测因素。

要点

  • TACE术前肿瘤硬度<2 m/s或肿瘤与非肿瘤肝硬度差<0.5者更可能获得治疗反应。
  • 肿瘤硬度及硬度差与TACE治疗反应显著相关(p=0.019和0.010)。
  • 肿瘤硬度特征可能作为TACE治疗反应的附加预测标志物。

核心结论

  • 肿瘤硬度特征可能作为肝细胞癌患者TACE治疗反应的附加预测标志物。

研究设计与样本

  • 回顾性队列研究,纳入59例接受TACE的不可切除肝细胞癌患者,TACE术前使用声辐射力脉冲成像测量目标肿瘤及非肿瘤肝组织硬度,以mRECIST标准评估治疗反应并分析生存。

关键影像表现/征象

  • 声辐射力脉冲成像测得的目标肿瘤硬度及肿瘤与非肿瘤肝组织硬度差与TACE治疗反应显著相关(p=0.019和0.010)。
  • 肿瘤硬度<2 m/s或肿瘤与非肿瘤肝组织硬度差<0.5的患者更可能出现TACE治疗反应。

诊断标准与关键数值

  • 以mRECIST标准评估TACE治疗反应。
  • 肿瘤硬度<2 m/s或肿瘤与非肿瘤肝组织硬度差<0.5与更可能出现的TACE治疗反应相关。

临床应用与阅片要点

  • TACE术前声辐射力脉冲成像测得的肿瘤硬度及硬度差可能有助于预测治疗反应。
  • 单变量分析显示肿瘤与非肿瘤肝硬度差(p=0.039)是总生存期的显著预测因素之一。
  • 多变量分析中甲胎蛋白(p=0.006)和BCLC分期(p=0.017)为生存的独立预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate whether elastic (stiffness) characteristics of tumours were associated with treatment responses and survival of patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE).

MATERIALS AND METHODS: A retrospective cohort study of 59 HCC patients with unresectable HCC who underwent TACE was undertaken. Acoustic radiation force impulse imaging (ARFI) was used to measure tissue stiffness of the index tumours and non-tumoural liver before TACE treatment. The correlation between the parameters of tumour stiffness and treatment response to TACE was assessed using mRECIST criteria as well as according to patient survival.

RESULTS: Tumour stiffness and its stiffness difference between tumour and non-tumoural liver were significantly associated with tumour response to TACE (p=0.019 and 0.010, respectively). Patients with tumour stiffness of <2 m/s or stiffness difference between tumour and non-tumoural liver of <0.5 were more likely to have treatment response to TACE. Univariate analysis showed that the difference in stiffness between tumour and non-tumoural livers (p=0.039) was one of the significant predictors of overall survival (OS). In multivariate analysis, alpha-fetoprotein (AFP) (p=0.006) and Barcelona Clinic Liver Cancer (BCLC) stage (p=0.017) were identified as independent predictors of survival.

CONCLUSION: Tumour stiffness characteristics might be an added predictive marker of treatment response to TACE in patients with HCC.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Chen R, Kong W, Gan Y, et al. Tumour stiffness associated with tumour response to conventional transarterial chemoembolisation for hepatocellular carcinoma: preliminary findings. Clin Radiol. 2019. PMID: 31421865. doi:10.1016/j.crad.2019.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。